Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample

Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report

Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology

Philogen updates on Fibromun clinical study developments

FIBROSARC did not meet its primary PFS endpoint in the final analysi

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies